IBDEI1LZ ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25709,0)
 ;;=R63.4^^107^1223^33
 ;;^UTILITY(U,$J,358.3,25709,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25709,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,25709,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,25709,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,25710,0)
 ;;=R63.5^^107^1223^32
 ;;^UTILITY(U,$J,358.3,25710,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25710,1,3,0)
 ;;=3^Abnormal Weight Gain
 ;;^UTILITY(U,$J,358.3,25710,1,4,0)
 ;;=4^R63.5
 ;;^UTILITY(U,$J,358.3,25710,2)
 ;;=^5019543
 ;;^UTILITY(U,$J,358.3,25711,0)
 ;;=R64.^^107^1223^50
 ;;^UTILITY(U,$J,358.3,25711,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25711,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,25711,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,25711,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,25712,0)
 ;;=R68.3^^107^1223^55
 ;;^UTILITY(U,$J,358.3,25712,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25712,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,25712,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,25712,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,25713,0)
 ;;=R73.01^^107^1223^94
 ;;^UTILITY(U,$J,358.3,25713,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25713,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,25713,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,25713,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,25714,0)
 ;;=R73.02^^107^1223^95
 ;;^UTILITY(U,$J,358.3,25714,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25714,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,25714,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,25714,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,25715,0)
 ;;=R73.09^^107^1223^18
 ;;^UTILITY(U,$J,358.3,25715,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25715,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,25715,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,25715,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,25716,0)
 ;;=R73.9^^107^1223^89
 ;;^UTILITY(U,$J,358.3,25716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25716,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,25716,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,25716,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,25717,0)
 ;;=R76.11^^107^1223^147
 ;;^UTILITY(U,$J,358.3,25717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25717,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,25717,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,25717,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,25718,0)
 ;;=R79.1^^107^1223^3
 ;;^UTILITY(U,$J,358.3,25718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25718,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,25718,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,25718,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,25719,0)
 ;;=R82.5^^107^1223^74
 ;;^UTILITY(U,$J,358.3,25719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25719,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,25719,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,25719,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,25720,0)
 ;;=R82.6^^107^1223^30
 ;;^UTILITY(U,$J,358.3,25720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25720,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,25720,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,25720,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,25721,0)
 ;;=R82.90^^107^1223^29
 ;;^UTILITY(U,$J,358.3,25721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25721,1,3,0)
 ;;=3^Abnormal Urine Findings,Unspec
